Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease

Cochrane Database of Systematic Reviews

Volumn , Issue 1, 2009, Pages

  Preiss, Jan C ^a   Timmer, Antje ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b German Cochrane Center   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABT 874; ANTIINFLAMMATORY AGENT; IMMUNOMODULATING AGENT; INTERLEUKIN 12P40; INTERLEUKIN 12P40 ANTIBODY; INTERLEUKIN 23; INTERLEUKIN 23P40 ANTIBODY; PROTEIN P40; UNCLASSIFIED DRUG; USTEKINUMAB;

BIBLIOGRAPHIC DATABASE; CLINICAL TRIAL; CROHN DISEASE; DATA ANALYSIS; DATA SYNTHESIS; DRUG EFFICACY; DRUG SAFETY; HUMAN; IMMUNOMODULATION; IMMUNOTHERAPY; INFORMATION RETRIEVAL; META ANALYSIS; OUTCOME ASSESSMENT; QUALITY CONTROL; REMISSION; REVIEW; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

EID: 70249112585     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD007572     Document Type: Review

References (18)

1. Akobeng AK, Zachos M. Tumor necrosis factor-alpha antibody for induction of remission in Crohn's disease. Cochrane Database of Systematic Reviews 2003, Issue 4. [Art. No.: CD003574. DOI: 10.1002/14651858.CD003574.pub2; MEDLINE: 14974022]
2. Alfadhli AAF, McDonald JWD, Feagan BG. Methotrexate for induction of remission in refractory Crohn's disease. Cochrane Database of Systematic Reviews 2004, Issue 4. [Art. No.: CD003459. DOI: 10.1002/14651858.CD003459.pub2]
3. Bernstein CN, Blanchard JF, Rawsthorne P, Wajda A. Epidemiology of Crohn's disease and ulcerative colitis in a central Canadian province: a population-based study. Am J Epidemiol 1999;149(10):916-924 [MEDLINE: 10342800] (Pubitemid 29230706)
4. Faubion WA Jr, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001;121(2):255-260 [MEDLINE: 11487534]
5. Feagan B, McDonald JWD, MacDonald JK. Cochrane Inflammatory Bowel Disease and Functional Bowel Disorders Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs)) 2008, issue 2. Art. No.: IBD.
6. Fuss IJ, Marth T, Neurath MF, Pearlstein GR, Jain A, Strober W. Anti-interleukin 12 treatment regulates apoptosis of Th1 T cells in experimental colitis in mice. Gastroenterology 1999;117(5):1078-1088 [MEDLINE: 10535870] (Pubitemid 29512666)
7. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008]. The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org.
8. Jacobsen BA, Fallingborg J, Rasmussen HH, Nielsen KR, Drewes AM, Puho E, et al. Increase in incidence and prevalence of inflammatory bowel disease in northern Denmark: a population-based study, 1978-2002. Eur J Gastroenterol Hepatol 2006;18(6):601-606 [MEDLINE: 16702848]
9. Kasper LH, Everitt D, Leist TP, Ryan KA, Mascelli MA, Johnson K, et al. A phase I trial of an interleukin-12/23 monoclonal antibody in relapsing multiple sclerosis. Curr Med Res Opin 2006;22(9):1671-1678 [PUBMED: PMID: 16968570] (Pubitemid 44449223)
10. Lawson MM, Thomas AG, Akobeng AK. Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis. Cochrane Database of Systematic Reviews 2006, Issue 3. [Art. No.: CD005112. DOI: 10.1002/14651858. CD005112.pub2; MEDLINE: 16856078]
11. Loftus CG, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Tremaine WJ, Melton LJ 3rd, et al.Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940-2000. Inflamm Bowel Dis 2007;13(3):254-261 [MEDLINE: 17206702]
12. Loke YK, Price D, Herxheimer A, Cochrane Adverse Effects Methods Group. Systematic reviews of adverse effects: framework for a structured approach. BMC Med Res Methodol 2007;7:32. [DOI: DOI:10.1186/1471-2288-7-32]
13. Mannon PJ, Fuss IJ, Mayer L, Elson CO, Sandborn WJ, Present D, et al. Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med 2004;351(20):2069-2079 [PUBMED: 15537905] (Pubitemid 39482500)
14. Neurath MF, Fuss I, Kelsall BL, Stuber E, Strober W. Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med 1995;182(5):1281-1290 [MEDLINE: 7595199]
15. Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008;371(9625):1675- 1684 [PUBMED: PMID: 18486740] (Pubitemid 351671883)
16. Pearson DC, May GR, Fick G, Sutherland LR. Azathioprine for maintenance of remission in Crohn's disease. Cochrane Database of Systematic Reviews 1998, Issue 4. [Art. No.: CD000067. DOI: 10.1002/14651858.CD000067; MEDLINE: 10796482]
17. Sandborn WJ, Feagan BG, Fedorak RN, Scherl E, Fleisher MR, Katz S, et al. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology 2008;135(4):1130-1141 [PUBMED: 18706417]
18. Solberg IC, Vatn MH, Hoie O, Stray N, Sauar J, Jahnsen J, et al.Clinical course in Crohn's disease: results of a Norwegian population-based ten-year follow-up study. Clin Gastroenterol Hepatol 2007;5(12):1430-1438 [PUBMED: 18054751] (Pubitemid 46633816)